NASDAQ:XFOR X4 Pharmaceuticals Q2 2025 Earnings Report $2.83 0.00 (0.00%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$2.84 +0.01 (+0.21%) As of 10/2/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast X4 Pharmaceuticals EPS ResultsActual EPS-$3.47Consensus EPS -$4.53Beat/MissBeat by +$1.06One Year Ago EPSN/AX4 Pharmaceuticals Revenue ResultsActual Revenue$1.97 millionExpected Revenue$1.62 millionBeat/MissBeat by +$350.00 thousandYoY Revenue GrowthN/AX4 Pharmaceuticals Announcement DetailsQuarterQ2 2025Date8/8/2025TimeBefore Market OpensConference Call DateFriday, August 8, 2025Conference Call Time4:00PM ETUpcoming EarningsX4 Pharmaceuticals' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled on Monday, November 9, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) X4 Pharmaceuticals Earnings HeadlinesX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 1 at 4:30 PM | globenewswire.comX4 Pharmaceuticals, Inc. (XFOR)September 26, 2026 | finance.yahoo.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it. | Banyan Hill Publishing (Ad)X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare ConferenceSeptember 9, 2026 | globenewswire.comX4 Pharmaceuticals Announces Positive Outcome From FDA Type C Meeting And Provides Update On 4WARD Phase 3 Chronic Neutropenia TrialSeptember 8, 2026 | marketscreener.comMX4 Pharmaceuticals Announces Positive Outcome from FDA Type C MeetingSeptember 8, 2026 | globenewswire.comSee More X4 Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like X4 Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on X4 Pharmaceuticals and other key companies, straight to your email. Email Address About X4 PharmaceuticalsX4 Pharmaceuticals (NASDAQ:XFOR) (NASDAQ:XFOR) is a biopharmaceutical company focused on developing and commercializing therapies for rare diseases caused by abnormalities in the immune system. The company’s research is centered on the CXCR4 pathway, which helps regulate the movement and distribution of immune cells in the body. X4’s lead product, XOLREMDI (mavorixafor), is an orally administered CXCR4 antagonist approved by the U.S. Food and Drug Administration in 2024 for patients aged 12 and older with WHIM syndrome. WHIM syndrome is a rare, inherited immunodeficiency characterized by chronic neutropenia, low levels of other white blood cells, and increased susceptibility to infections. XOLREMDI is designed to increase circulating neutrophils and lymphocytes and is intended for long-term treatment of the condition. The company’s activities are primarily focused on the United States, where it is commercializing XOLREMDI while continuing to evaluate mavorixafor in additional rare-disease and immune-cell disorders. X4 Pharmaceuticals was founded as a biotechnology company developing CXCR4-targeted medicines and became a publicly traded company on the Nasdaq exchange in 2019.View X4 Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Time to Nibble on MCD Stock After it Enters Oversold Territory?McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes NextTarget's Holiday Blitz: Slashing Prices to Capture Market Share Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
